TECHNICAL REPORT
Overview of EU/EEA and UK deployment and vaccination plans for COVID-19 vaccines
Scope of this document
As follow up of the EU vaccination strategy Commission Communications, this document outlines the
current development on deployment national vaccines plans, including recommendations for priority
groups, evidence considered for prioritisation of target groups, logistical considerations and monitoring
systems for safety, effectiveness, vaccine coverage and acceptance to be put in place.
Target audience
The overview is foremost intended for internal use (European Commission, Health Security Committee),
but could be made public at a later stage, once information from all the survey participants is available.
Background
The European Commission is currently working to ensure that there will be access to safe and effective
COVID-19 vaccines across the EU/EEA Member States encourages a coordinated approach of vaccines
deployment plans across these countries.
In its communication of 15 October 2020, the Commission presented the key elements to be taken into
consideration by EU/EEA countries for their COVID-19 vaccine deployment and vaccination strategy plans,
in order to prepare the European Union/European Economic Area (EU/EEA) and its citizens for when a
safe and effective vaccine is available, as well as priority groups to consider for vaccination first [1-4].
Considerations on introduction and prioritisation of COVID-19 vaccination in the EU/EEA member States
have also been documented in a recent ECDC publication [5] in addition to a WHO publication on strategic
considerations in preparing for deployment of COVID-19 vaccine and vaccination in the WHO European
Region [6,7].
Methods
The information provided in this report was collected from the following sources:
Survey
On 20 October 2020, ECDC sent by e-mail to the EU/EEA NITAG collaboration members (27 EU member
states, 3 EEA countries and the UK) [8], a brief survey with a set of six questions to gain an understanding
of current development of national vaccination plans and deployment of COVID-19 vaccines. Countries
were asked to provide information on their vaccine deployment plan (final or in development) and a link
to the document if available, information on priority groups for vaccination if selected, evidence to be
considered upon selection, logistical considerations and any product specific monitoring information. The
questions were open-ended.
EU/EEA NITAG collaboration dialogue meeting
As a follow-up to the survey, ECDC organised a dialogue meeting on the 23 October 2020 with the EU/EEA
NITAG collaboration (hereafter named NITAG collaboration) with invited observers from public health,
regulatory agencies, ministries, and the Joint Action on Vaccination (JAV) to enable countries to further
present details of their vaccination plans. Nominated NITAG collaboration members were invited to
present in two slides per country plans for selection of priority groups, overview of how selected groups
will be invited to vaccination and where vaccination will occur, how vaccination will be documented for
vaccinated individuals, by target group and by vaccine product, and how vaccine uptake, safety,
effectiveness and acceptance will be monitored.
2
TECHNICAL REPORT
Overview of EU/EEA and UK deployment and vaccination plans for COVID-19 vaccines
amount of skilled workforce available for providing vaccines, would be helpful. Country plans for vaccine
storage, transport and cold chain requirements will become clearer as further information about COVID-
19 vaccine characteristics become available, such as the potential need for additional ultra-low
temperature cold chain and how this will be managed.
Development of electronic immunisation registry systems for COVID-19 vaccine monitoring purpose is
ongoing in some countries with currently no existing electronic registry. Further description of these
systems is required to understand what type of information can be provided at point of clinical care, at
population level and link this electronic system with health outcome databases. In those settings where
no electronic system is planned to be deployed, a comprehensive overview of methods to be used for
monitoring purpose should be undertaken and guidance provided.
Several activities will be undertaken by ECDC to support EU/EEA countries in their efforts to prepare a
vaccination plan and to implement monitoring system to document safety, effectiveness and vaccination
coverage/acceptance: a periodical mapping of deployment plan for COVID-19 vaccines; mathematical
models on different vaccination strategies for various target groups and vaccines; close collaboration with
WHO EURO in order to align principles and actions through the development of the COVID-19 vaccine
framework in the European Region; close collaboration with the European Medicine Agency (EMA) for
post authorisation surveillance activities; close collaboration with the NITAG collaboration network, of
which ECDC acts as secretariat.
Contributing ECDC experts (in alphabetical
order)
Internal Experts: Karam Adel Ali, Kim Brolin, Silvia Funke, Kari Johansen, Nathalie Nicolay, Kate Olsson,
Lucia Pastore Celentano.
Disclaimer
All data published in this report are correct to the best of our knowledge at the time of publication.
Maps and figures published do not represent a statement on the part of ECDC or its partners on the
legal or border status of the countries and territories shown.
13
TECHNICAL REPORT
Overview of EU/EEA and UK deployment and vaccination plans for COVID-19 vaccines
References
1. Communication on the EU Strategy for COVID-19 vaccines. European Commission. 17 October
2020.
https://ec.europa.eu/info/live-work-travel-eu/health/coronavirus-response/public-
health/coronavirus-vaccines-strategy en
2. Communication from the commission to the European parliament and the council. Preparedness
for COVID-19 vaccination strategies and vaccine deployment. EC, Brussels, 15 October 2020.
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2020 strategies deployment en
.pdf
3. Coronavirus: towards a common vaccination strategy. Factsheet. EC, Brussels, 15.10.2020.
https://ec.europa.eu/commission/presscorner/detail/en/fs 20 1913
4. Communication from the Commission to the European Parliament, the European Council, the
Council and the European Investment Bank EU Strategy for COVID-19 Vaccines. EC, Brussels,
17.06.2020 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52020DC0245&from=EN
5. Key aspects regarding the introduction and prioritisation of COVID-19 vaccination in the EU/EEA
and the UK. Technical report, ECDC, 26 October 2020.
https://www.ecdc.europa.eu/sites/default/files/documents/Key-aspects-regarding-introduction-
and-prioritisation-of-COVID-19-vaccination.pdf
6. Strategic considerations in preparing for deployment of COVID-19 vaccine and vaccination in the
WHO European Region. 21 September 2020. Copenhagen: WHO Regional Office for Europe;
2020. https://apps.who.int/iris/bitstream/handle/10665/335940/WHO-EURO2020-1148-40894-
55356-eng.pdf?sequence=1&isAllowed=y
7. WHO Strategic Advisory Group of Experts (SAGE) on Immunization.
https://www.who.int/immunization/sage/covid-19 documents/en/
8. EU/EEA National Immunisation Technical Advisory Groups (NITAG) collaboration.
https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/national-immunisation-
technical-advisory-groups-nitag
9. Conseil Supérieur de la Santé. Stratégie de vaccination contre le COVID-19 en Belgique. Juillet
2020.
https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/2020101
4_css_9597_vaccination_strategy_vweb.pdf
10. NÁRODNÍ STRATEGIE OýKOVÁNÍ PROTI NEMOCI COVID-19. 07/09/2020.
https://www.mzcr.cz/wp-content/uploads/2020/09/N%C3%A1rodn%C3%AD-
vakcina%C4%8Dn%C3%AD-strategie-onemocn%C4%9Bn%C3%AD-covid-19_k-
ve%C5%99ejn%C3%A9-diskusi.pdf
11. Stratégie de vaccination contre le COVID 19 - Anticipation des scénarios possibles de vaccination
et recommandations préliminaires sur les populations cibles. Haute Authorité de Santé. Juillet
2020. https://www.has-sante.fr/jcms/p 3197106/fr/strategie-de-vaccination-contre-le-covid-19-
anticipation-des-scenarios-possibles-de-vaccination-et-recommandations-preliminaires-sur-les-
populations-cibles
12. Conseil Supérieur des maladoies infectieuses. RECOMMANDATIONS générales du CONSEIL
SUPERIEUR des MALADIES INFECTIEUSES, concernant la stratégie vaccinale contre la COVID-
19. Septembre 2020. https://sante.public.lu/fr/espace-
professionnel/recommandations/direction-sante/000-covid-19/000-covid-191-
annexes/recommandation-csmi-strategie-vaccinale-contre-la-covid.pdf
13. Nationell plan för vaccination mot Covid-19. Folkhälsomyndighetens delredovisning av
regeringsuppdrag S2020/04550/FS
https://www.folkhalsomyndigheten.se/contentassets/74cdc0cb9b3a4341827c65ba0c813a30/dn
r-s202004550fs-delvis-nationell-plan-vaccination-covid-19-2020-08-31.pdf
14. Joint Committee on Vaccination and Immunisation: updated interim advice on priority groups
for COVID-19 vaccination. 25 September 2020
14
TECHNICAL REPORT
Overview of EU/EEA and UK deployment and vaccination plans for COVID-19 vaccines
https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-
vaccination-advice-from-the-jcvi-25-september-2020/jcvi-updated-interim-advice-on-priority-
groups-for-covid-19-vaccination
Annex 1. Survey questions
Please respond by ticking relevant box and respond shortly to the open questions.
I represent the fol owing Member State: _________________________________
1. Is a vaccine deployment plan for COVID-19 vaccines currently under development or already available?
܆ Yes
܆ No
܆ Unknown
2. If yes, would you be able to share the document with ECDC? If in the public domain, please share
the link:
3. Have you developed recommendations for priority groups to be vaccinated in the initial phases of the
campaigns when vaccines are in short supply?
܆ Yes, please provide further information:
܆ No
܆ Not yet, but currently under development
܆ Unknown
4. What evidence will be/have been considered and by whom in order to prioritise the target groups for
vaccination (e.g. role of impact modelling of different vaccination strategies, enhanced
epidemiological surveillance, reported vaccine safety and efficacy by age and target group from phase
3 trials ...)?
Please provide further information:
5. Please provide information on how vaccines will be delivered (e.g. dedicated vaccination centres,
routine GP practices, pharmacists etc..) , how the identified target groups will be invited to be
vaccinated (invitation letter sent, …). Please provide further details on the organisation of
vaccination campaigns that can be helpful to others.
6. Please provide information on how product-specific monitoring systems will be organised to
document vaccine coverage, safety, effectiveness and acceptance.
15
t
e
e
d
e
e
the
b ze
ill y
e
si
ilit
ar
eres
e: For m
be
th
onal
to b
et s use
atch)
rse s:
e areb
rse
eForm r th
nc
he
e w
nce of
ers
tion
b
r the use
fro
till
s a
ation
dverse
should
w easib
d y
accine
th
s fo
a ial int
ases: s
ing t
elgium. For
ts,
:
adve cinee
ct (L
fo ic
adve
: notification
ct
grated rt
e f
c is
, v and
of ec
incide
en
ent p
national
uct
stem
g.
cord
of
roje
ppl
of heal
xpe
accina
nt
roje
pulation to d in B
ents
e.
GPs documentation =
pati re
(v
date type
ation to th
f sp
te
ate th
ate
rough ology
rod
specifie
ting
eb a
sionals
me
onsider
ound incide
ts by vac
ting ts by
of e
round vents, data
ted,
ss ts o
e
c
are ev
in ev stigation of kth
¾
por
por
ckg
estig
stim kgr
ned.
rta
thod
:
ot fully andard sy
r other vaccinations pec
Re even
particip ACCESS p
coordination) of a w
Re even
profes
through inte Panel
asse even
Ba rare
ACCESS p used
of the po vaccina
less r inv
to e bac
ce Inve
brea me
defi
pecific p
N St
fo ex
s
-
-
-
-
-
- -
ccine
Va monitoring
be
et
e .
tions
s,
.g
ainly
ified
rg
ec
al
m
or th
GP
s.
th
risis
ccina
on
si
y f
escue
tal ed ta
sp
eal
tate (e
va
fes h
ar
firstly
een
ther c
ospi
ic
o
ess
dentifi
bl
ec
will
d h
ot b
e that
e pro
rigade, r
ar
and
an
as n
abl
c e pu
th
ons n
s
accine
tion of i
f th
si
, fire b
v
tices
eal o
orities
tioning of the s
oups h
ofes
The given through routine
prac Invita
gr yet.
It is prob
of h staff
auth
pr func
police
-19 vaccine
ups
lth,
l
gro in
iona
for COVID
et
17
ent
arg TAG,
d t
stry of Hea
nd profess
d by NI
oritise are
s of Mini
ntific a
f pri ep
nt
o pr
cie
and vaccination plans
rtme
ies.
ent
ill be
ciet
m
A draft w
consultation with differ depa
NIPH, s so
eploy
t
ic
r
d
e
tha
t
l
ve
)
r
b
y
:
ain
an erious
ica
(s
nd ed
the onom
t
ert es
ct
ist
sease,
of the
Fo
en
ases,
e. on
n a
as -ec in will .
tra
olog
rious li
romis
urrentl
ith c iseas
res
ey di
/EEA and UK
accine
labl ata
well socio orig owed
elopm
erious tory
es, ension, s
c dise
toonc
idn
EU
enicity
vai
as
ic
but c
ple w
. s
ert
ia
ase, se
of
a
t,
.g spira seas
rd
d k
w
ple, d
ents act of
ely foll
Peo chronic d
(e re
di hyp
ca BMI > 40,
hema
dise an
rvie
pe(s) of v
ill be am
immunog ty
w ex
pregnant wome immunocomp
pati imp
and ethn
clos
Not ye under dev
-
Ove
s.
RT
Ye
REPO
NICAL
TECH
echia*
Cz
l
ter
sing
ed
rugs.
tion
ark
or ech
r
th
cal tem
d
gis
to the urance
/) wil
s
be
with
the
blic
ll
link
erage
re
ns
e for
cy
s
ptance:
nd d
Cz
egula
valuation
f bo
edi rs
ected
hing for
uction of ls in l e d fo adverti
e.
er a
Denm
d to
em
ukl.cz
, as
l be
yt
s a
gen r r
rod
d m owe
ilarly,
ial interest
porting
.s
in
er
nstitute f
t a
nica
ing o
t on Pu
ake, cov
suspecte
scharge
re health i
information syst
w
s p
egist
en
fe p utica
It
r
to monitor
Sim
lanne
pec
ness, acce te Institut
accines accine
ible fo
ce
, cli cines an
ket
e electronic
istry
s.
king
l di
tate I
m
sa
f s
¾
es.
gister wil
Sta
Control (SÚKL - ://ww see ev
r v
Control is a
edi
cines an
ry to
es
is p
t o
ctive
id v
ic
m the Ac alth Insuranc
y lin
tions and sel
spita
he S
vern spons
d mar
edi
re
gistries ecific upt
ffe The
Drug http
over
cov othe
Drug
go re
of the pharma
country of m
monitoring the an
m dev
fro He
dato
b
ation reg
afety
reac even
, e
an
fectiven
s
e
ty -
-T
uct sp
the ho
fe
cinations in th
d ef
cine
ers erse
m
Sa
It is m vac
immuniz (DDV). This
to other re prod
an
vac monitored
adv adv
fro
s
e
is
e at
on
GPs
re
nt.
ac
ill b
ing
ns is a nd
cinati
e a
vaccine
a
e pl
aig
, w
.
ak
ed on the cines w
ber of
w the
mp
etc
work
evelopme
ill t
or vac
ntly
Or through
ios, includ
d/
ac
d
this
r d
e.
v
an
num
s, ho
e defin
tion ca
tc.) w ac
s
hat
Curre
cenar
y in
s
elivere
unde
, e
tal
f w
ed. on a
roup
s
s
nt
d
riorit
em
ospi
is to b s o
ing
et g
h ntre
rg
ill be
syst the workpl
+ ce
This basi
approv work
differe ta
w
Communica key p
currently
-19 vaccine
t
en
WHO.
g,
to
ish
ffer ach,
ve-
ble ters
for COVID
an
di pro
goin
abo n
18
is
t a
ave ap
e i
ork e D
e
he
ernational
no
is on-
parame
ll t
ultipl
ho h
ts ar
ng th
A
all
en
cine w m
m int s HSC, ECDC,
ed.
by
lopi
ocess
urrently
em
vac
cies w
pr
st of
el
eve
e fro
e c
such a
li
iew
nated
n d
ar a
onsider
and vaccination plans
th agen s i
ev
ent
ng c entioned
m
Denmark’s coordi
heal task
with advic agencies
The r
and we provide
bei m
eploy
s,
d
l
ff
in
ICU,
er
f
.
l ers,
ta
s
S-
both
y
(
risis
.
and
t
f o
.g
edica
,
scue
nica
tition
ce,
cal
orkers
les)
al
gy
er
en
re als
af th
y m
vi
years of lder
st
es (e
cli
re work
ry w r SAR
vices
nd
ritic ture
ed re
ent, c es)
urrentl
/EEA and UK
form of s)
eal
ing
ations
amp
sion
iologi
en
h
enc
f c
m
d o
rm
e fo
ser
a nnel)
truc
elopm
EU
ete
ted
ers,
le 65
fes
ic
lthca
eral prac rg
ue ser
o
grat
dem estig rato
-2 s
so
vice,
an
but c
of
ab
alth ca
ected bl
ec
ents
vern
t,
w
serious di
He pro
sel pu
authoriti
sel
hea
gen eme
resc perfo
epi inv
labo charg
CoV Social
cli per
Staff infras
(inte ser
work
go committe
Peop age
rvie
-
-
-
-
Not ye under dev
Ove
s.
RT
Ye
REPO
NICAL
TECH
Denmark
-
er
e
ly
tion
e
ge
e
ns
om
f
und
,
,
ter,
d
e
pact
is
rred ativ
cina
ptance
the
y o
an
cluded
ntly
low th
n b
ing
reg
e nam
efe
vac ers fr
cce
enc
e im
erage
stry
ad
on usa
on
neg
s
under ation.
l
lectronic
vaccine
ersonal
pr
e monitoring
ot ex
cov ety:
n nd adverse
egi
ber
ata
plify
gn est
es
work current includ
ge, a
e
nsur
e p
gister a
inistr
te Ag
r e
nned.
accine
la
ing saf
s a
ssible through
of tr um
e d
at t
r th
entine ce n
era
s ar
tion curre
d
re
t n
ity
atch numb
es
g p
t lice
etwee
t po
lation r
er
id
fectiven
lan
b
adm
der Sta
b
rugs which ca
d to am erstanding
ergoing
ein
s an
pu
ccine
cording d Lo
sign fo
rvei
paratory
cussion with clinicia
nd
includ
ard
accina
ent with WHO
se of s
b
es
Link outcome
even national v
po nation-wid
numb Va
re an
Insuranc of d
use und
morb
Cohort desi rather th
de of ef
U su
Pre und
dis
tion cov
un
s.
ide pos
ing
fectiven
is
uct a
icine
ntly
-
-
-
-
-
-
ccina
d ef
fectiven
with information about prod
DDV.
Va
an health bo
Safety
Med
Vaccination card fo proof of v
developm
Curre
Nationw
monitor ef
s,
o
.
t
y
e ith h
ure
n
ed
in
nd
cine
bilit
at
be
ration
w
e th w
e
iver
g and
t, per
tore a
accinators
in
sponsi
as muc f th
tilized
em
ds to orking o
e del s
v
s by la
e to us
t
w.
conside
re
tion
e w
ase o
ill b
ur local vac
communication
under
es u
low
alitie
c
r produc a- in nee
tical
ccine
fo
the
y hop
is
t.
ight no
l va
accina
hey ar
d to en to the
ss of notify and
s are en
ocess
cha
v
Pfize
T
ls r
log
te
gn
municip
ible. In
s
accines w ntra
cold
bu s. Th
roce tions
nd. The
nza ss
etai
ce
p
elopm
ing pr
tional ultr
T)
stri
the
ist
po
ovided.
For the
the v the
di store
The invita
campai dev
Vaccination is
of
Finla ex
influe as
BioNTech/ addi
(UL pr
the d
-19 vaccine
d
ts,
e
ta,
m
en
, ll b
s.
ls an
case
nt
fro
ia
the
se
g using
od)
ere
for COVID
include
ce da
t u
m
19
ed
ata al decisions account
ellin
ed pati
llan
d
-19
what wi
the
e III tr
get group
fin
eren
eas
rvei
into
(Poly
and
has
ff
and
VE of diff
uring
onsider
ata
c
su
ations from
s. The
king
d dec
ata
cal
nd
de di
vi
idates.
ased on mod
of COVID an
ent of tar
o be
de ta
nd
ata, ECDC
ndations
b
ata
ion d
ized
eration d
ce t
iologi
ill pro
t matrix d
ca
and vaccination plans
sults from p
comme
r countrie
e ma
h d tal
n about the
re
re l NITAG.
w
ent
velopm
den
dem
comme
L w
nsmiss
m
consid de
Evi
epi clinical d
re othe
will b the
the loca
TH
scenarios
Finnis hospi
contac tra
kno vaccine
eploy
d
s
s
f
ain
s o
y
orker
rker ert
t.
s ar
wo
en
re ith c
itie
lder
0 ye
urrentl
/EEA and UK
id
d o
l ca e w
e 7
elopm
EU
lthcare w
pl
pl
an
but c
of
ea
t,
w
H
Socia Peo
comorb Peo
age
rvie
-
- -
-
Not ye
under dev
Ove
s.
s.
RT
Ye
Ye
REPO
NICAL
TECH
tonia*
Es
Finland
s
e
-19
m
ional
e
il b
stem
,
lai
.
tal
VID
s)
d w Nat
stage,
s in
ase-
s
t sy
ntral
depend on
SI to
eys
rvey hospi
an
en
em
view
rance c
d c
y the
that
ce abase er
be
se
ome
t
urv
for CO
are
y.
ffer
d
yst
erall
t su ong
so
d
udies
y)
s will
s
an
d b
en
en
ba
ed.
und
st
m
te
enc
di
e. At
on one
d insu
ente ness:
tud
t pl
es
ng an nc
ill al
ing ose s
n ov
qu
ed
nd-alone
tal-
blish
yste en
tudies
ss
l th
ke:
ta tronic dat
elopm
phone
f, an w
lem ctive
onduc
ippi igila
ec
rveys am
on which ICD to cod health outc
sta
ce s
sse
al
ave a
A s el
currently dev
Tele
(subse su
staf data
imp ffe
Target (hospi
control s
e
y c
ealth Ag
tion (SI) to monitoring
sh cov is work ate
upta
e
eploym
H
e,
ce po
eg
-
-
-
rag
nce
er to h
ccine
ccine
Not yet
Monitoring s the d
Acceptan regularl
Public
Fran informa
sto pharma
Fra aggr
ord
Va
Va
r
he
ill
nde
deral
vel.
e w
r
le
ill be
fo
ussed at
still u
ation on t
e
w
ly w
se
lan
isc
lth’s nd
ha
d d
ndate of fe
nder like
rs.
der in the
gram
l p
ent p
l u ost
nte
accine is t an
y of Hea
M
comme
onsi
pro oon.
e ma
oym
en
tr
d sti
initia
pl
-19 v
re
entation of th
an
tion ce
s
to c
the
elopm
Minis
is in th
neral
lem
cination
es ussions.
in
sc
ccina
The de
COVID dev
the Ge
points imp
vac published s
This
stat di
use va
-19 vaccine
e
so
e.
m
seas
e
om
labl
ors
n
ill be
in a
ill al
,
di
onal
ill b
s fr w
for COVID
si
include
ch
ed
s:
ce, a
20
ce w
vaccination est sult up s avai
ed
ial
,
esults fro
evere
ofes
ermore
llan
Fren
llan ons w
ent e t
ill be
on a
al tr
d r
e gro
elling
rvei
of s
f pr
rvei
el. Re
s on risk fact
iffer ill b
so
onsider
linic
es w
ew
d o el as
d
as
c
c
. Furth
di
c su onclusi
view
mod
cal su
evi
at w
s w
C
ed
m
ework an
.
efine th
ion mod als by ag
o be
re fro afety tical
ce stu
re a
iologi ered.
es
tri
ce t
atic
, s ma iologi
ered
and vaccination plans
ture r
cy
ra
actors an su
id
d to d egi
ical
onsider
data
id
ent
po
dem
nsmiss
den
the
dem
ceptan
m
Lite
risk f ex
epi cons
use strat
tra clin
be c
Evi
system and
effica ma
epi
ethical fram ac
cons
eploy
r
d
s
f
sk
d
ed
e
e
ers
s o
e o
s e
ribes
nt
b
he
th that
y
orker
er ri
os
e ne
ar
as
ristics
t.
T
er
work
se
esc
ari
ly. Th
ios,
ill be
en
re
lder
d
5 ye
t high
e to
g conditions
tion wa
en iffere
ar
nd th ses. tion will
elling
oon as
urrentl
/EEA and UK
d o
in
so
en
y und t w
l ca e 6
e a
ere di du
liminary
to d
s, a
s s
en
elopm
EU
lthcare w
pl
an pl
erly
nda
nda
e.
but c
of
ea
ed in Ju
ent al erent anticipate
ing
ic sc nt characte
cine do
t,
w
H
Socia Peo
age Peo
of sev death
und t pre
ish
labl
bl
cum
cination sc
dem
accine
dated a
currentl elopm
rvie
firs
comme
comme
sults of mod
-
- -
-
A
re pu
do the diff
vac accord
epi differe
of v of vac
re
up re
are dev
avai
Not ye
under dev
Ove
s.
s.
RT
Ye
Ye
REPO
NICAL
TECH
e
rmany
Franc
Ge
d
se
or
an
f
ess
vs- ba
ities will
talian
er
try.
ent
em
st
es
ground
rveys
m
or
y: yst
he I
(using
ys
egis
f
t
egi
ack
fectiven
served- al
b
:
t su
ce s
tudy
cy r
s
form
d ef t by
ob an
en
develop
at
Safet llan
en
an
ence
ptance
er
ts an
pected
cination R
accination activ
rvei
ency.
afety:
outine
Cohort s
app) Pregn
R ex
on country incid
cce
Subsequ
und
g v
elopm
s
a
tronic pl
ec rin
eness and ific su
-
-
-
-
ntly
sed.
ec
ccine
ccine
ste
ctiv
erse even er dev
gi
dicine Ag
Va
Va
National Vac
Curre
The el re
be u
Effe A sp
adv und
me
r
ly
n
fo
be
ly
r
een ful is
ay
er of
ding o ps
ed.
pen
se
uat
es.
derations
. Othe
yet. It
de
spects, Ita
val
ntr
numb
g grou
ve not b
cines m
s as the
s in
a e routine
e
s of
vac
in a
accination and bility.
ervices o increa
re ce
s ha a
at
volve
r v
t
ill be
e
aila
istical to us
istical consi
includ
ined
setting
e th
tered
gn
d fo av
tion s lities e w
s
lthca
les
te
ing
log
accine
bl
bi
v erm
pai
ssi
rge
look
ssi
At hea
The
the det
po
adminis different
cam variab
ta vaccine
For the log is
vaccina po
coverag
-19 vaccine
e
nd
ng
of
y the
n
tegy
rature
y a
ines
y
s
data uenc
b
ls,
aki
isk,
del
ork.
sease
ups,
for COVID
d b
lite
infl
iolog
di
bility of
ccine
ons t
ristics
21
ere
e withi ew
aken
ation i
l tria
t
ase r
gui
l li
gro
ce,
aila
ific
. Va ) will
cte en .
ation Stra
WHO.
h t
isk
dati
dise
and
wil
ac
ioritiz
pec clinica
ess
group will en
ffer
gies
ernational
l epidem
justi
n r
-s
ations.
chara
r pr
ty, av
di
m
rt m
te
be consid
int
erial
hical fram
ppro
asibility
nd
ations
a
ccine
tiven
xpe om
nd
tra
NIAC/NITAG.
es
loca
e et
quity,
verity i socie
fe
a
will
tatus on
nd
fec
e mat
eral
ef
rec
-19 Immunis
n e
ering
, se on s, va
comme
count the ccine
and vaccination plans
nce
includ
nt s
opriat
rate
ed o
en act
d hoc e
ent
ide
comme
rd
erational
abo
m
Ev
COVID Group and
This
consid curre
referenc form CDC, PHE and
Re appr
The gen
NIAC/NITAG fo bas
bu imp
vaccine information fro
op (safety,
final re
An a el
into ac the va
vaccination s
eploy
d
y
y
y
t.
t.
t.
en
en
en
urrentl
urrentl
urrentl
/EEA and UK
elopm
elopm
elopm
EU
but c
but c
but c
of
t,
t,
w
rvie
Not yet,
under dev
Not ye
under dev
Not ye under dev
Ove
s.
s.
s.
RT
Ye
Ye
Ye
REPO
NICAL
TECH
d
d
an
an
Icel
Irel
Italy
)
s
-2
n
(ad
r (E
ber
o
der
)
se
case
e
e
d to
gn
accine
vi
)
em
ailor
t
S-CoV
aba cy
ai
y)
ate
,
d t
e-tool
en eminde
tion
tion tool
llanc
dat
cinat
ept
pe
-19 v
ystem
ei
amp
SAR
s
icac
urvey)
re
sting
tion
cine pro
effica
in S
nd an
a c
VID
t:
intm and r ent s ccina
gistra
ith
ase
eff
be
te
O
ac
(
en
en
e surv
edi
v
ppo
te re e w
se
tion s
tre
cale
gistra
tion
ing
aigns.
or C
d a
tive c accine
ba
ula
e m
e s
f
liver va
ccine
si v
ist
elopm se by
rtifica
:
op
e the
mp
ex
rg
em
U
Sen invita
appointm De
ce Va
Linkag
po (Æ
Link with COVID-19 data
ovigilanc
Intention to vac
(p undertak
Survey to se
ca Larg
la
te
.
-
-
-
-
-
-
em
ptance -
-
-
para
Vaccination re hoc syst
under dev
Se pharmac
syst
Acce
ll
s
o
wi
e
ible
are as
te
es,
ency
nd
cine,
ost
te lation
e
thc
nned t
being
e es.
d
ourc
is
Ag
, a
pu
with th
ent
d
if fe
.
an E-
stima
e vaccine
it
e vac
he m
th
e.
thos re not
pla
accina
an
oym T
al
th
State
tions
blic various
f th
s, heal
esourc
n res
pl
get
e NITAGs
l work on a
dicate
g into
n r
ntre
ractices rs are
ystem. Vaccine
ed to e ateri
ing days th
ccina
e pu
in
r de
esident po
d that
s wil
ent o
P p
logistics are
ountry.
e is to v
m
huma
en for fre
at
e de
ette
t is to
e r
. Ne (
iv
taff who a
edia on
b
look ent s
s:
olow
with the
ctiv
l s
oym
s for HCW, and
e huma
t.
he c
je f th ays
s
anne e g
dicine
ts.
pl
s and
ned th
ther
r/document to ca
ts in va
of m
tics) G
ntly
uat
o
eed
tics, IT,
the f
inform th
ec
is
eloped fo
cult par
ob
an
di
tte
per
so lp
pointm
ntre
ross t
ffi
e n
c)
It is pl will b
In pl
toge of Me
le me
ex
al he
asp
For de there will
vaccination ce facilitie
(log Invitation l
be sen Curre ap ce dev ac di adeq
The 70%
in 90 d th
logis et
-19 vaccine
cy
e
ing
ssion).
the
ge, and
te
not in
ble r further
gy.
for COVID
effica
nsmi
look
ora
22
s sta
fo
ible changes egy).
surveillanc
trate
accine
tra tional s availa low oss strat
at thi
p
ention of
al
h a
nd
e currently
iologic
tool to inform ation s
t the v
uc
ation
m
prev
ar
tion to incorp
rmation
tic infection (and
ata) will
ent (a
pide
elling ioritis
g tha
the
tion (s
m
ourg
bora
prioritis
and vaccination plans
in toma
evention of the
mb
mod
orporation of addi
ent
lies
m
Basic info assumin
re symp
the pr Inc
informa national d
develop in the
Luxe
for colla national e
into a national pr
eploy
r
d
er
s
f
s le
r
r
s o
e
y und
orker
ar
orker eop
)
ar
s fo
lder
to efinition fo
:
5 ye
ility
ries er furthe
/EEA and UK
t
d o
ble p
ing
t.
urrentl en
roup
e
e 6
ra
en
EU
lthcare w
pl an lthcare w
atego und
of
t, c
isk g
seas ea
ea
ccord
c
w
elopm
R severe COVID-19
di H
Peo age
H Vulne
(a national d
COVID-19 vulnerab
elopm
rvie
Not ye dev
-
-
-
- -
These currently
dev
Ove
s.
s.
RT
Ye
Ye
REPO
NICAL
TECH
a*
Latvi
Luxembourg*
e
f
le
em
e
ic
o
e
pt of
st
ency
ntr
der
tform.
bl
-up
ge
nc
the
d
ce
ctive
altes
ag
un
f Pu
y
g pla
injury
nce
llow
vera
eness,
eilla
base (MSIS
n
e conce y an
effe
he M
icine
tin
ila
or
fo
r
ata
).
genc gia
th
.
ig
tute o
se
onitoring sy
t.
f t
xis
e f
ectiv
tion co
n Surv
d
):
currently
cov
nsti
bl
n fo ff
OVID-19:
(MSIS) and
for Communicab
ying
en
monitoring
/e
gia
em
immunit
oning
nsi
ataba
ific m
st
stry
:
cy)
an I
cy
tem
eases
edicine a (Norwe
ec
andate o
ss
ational
afety
boratory
lly
conve herd
coco
elopm
national med
egi
Through e
N
pharma (s
agen
egi
espo
ffica
Norwe Sys
Dis la
Lab d
n m
entation of an -sp
ion.
ene
rw
e
nd vaccina
m
:
:
shing a pla
ilance of C
gia
ration sy
duct
-M
uss
ctiv -
-
th is r
bli
ty a
-
st
sc
eal
ctronica
Imple pro
under dev
Safety
National r
di
Effe
Safety
The No
H
esta vaccine
safe Surve
Norwe ele
regi
s
n
lu
s,
be
e n
It t
e
g f
e
n
y
e o
y. oun
till in
e the
tin
ayb
ow
alit m
group
cid
thes
is
eration e
ystem
urrent
kn
er
d
vaccinatio
ex
vaccine
l
ill likel s
l de
he a
ss is s
involv
ual
r
e th
w
an
he c
but m
vid
the
ot yet
ze
municip
cines.
roce T
priority
rsons in
t.
s (
consid
ls for
istica
re und
hey xisting
re best delivered si
on t
ac
p
a
indi
end fo
an
e n
T e
ality wil
nd
ase.
pe
en
vaccination wher
s a
to use
ar
log
t.
d v
istical
pe
ph
the
att
s).
ls
an is to us
en
nza
te
nt thoughts
to the
to intm
ans
tion pl
tai
log pl
ibu
s
lanning rly
tion of
po
g channe
erations
bu
accine
accine ed
tin
lso de
str
ea
vale
v
elopm ed on the
entification of
o pl
stri fine thi
ivery.
l a
The p an
pre id
and then invita
groups by ap
Als
di re
The de
for the but the
exis del
The
consid
dev bas
for influe each municip
how v adjust
conditions in the wil
of di
-19 vaccine
e
e
ar
will
y
ct
tion ccine
of
d ls
f
ls
o
es,
d
safety
lso b
derations
va
ria
ria
s
idity /
get
red b
for COVID
e an
tegi
e an
ation
23
accina rted
e 3 t
elling
cal
e 3 t
will a
up.
v
ag
vaccine ag
d tar
d consi
as
stra
epo
y
y
has
r for
d vaccine
ph
rs.
mod
iologi
p prioritiz
get group
for morb e
elling
e conside ry gro
erent
y b
y b
ge an
he r
m
pilla
act
m
b
-facete
iff
porte
viso
d t
icac
dem
eported icac
labl
actors
y a
mod
eff fro
nt
imp
, r eff fro
s.
vai
re y b
will ad
ken. The role of impa
of d an
d
d
sk f a
es
orta
of
vaccination
nce
roup
to conside
tion of tar
nt
ity,
icac
thics ernal
and vaccination plans
ral multi e ta
e ri
elling egi
y an t group
illa
nce
role
y an
et group sed to inform
et g
eff
up.
d. E
ent
ve
rat
rge
hanced epi
rg
rg
ide
d
m
Se will b
mod st
safet ta
two imp
The
differe en
surve safet
ta be u
ta
Ev
prioritiza
includ mortal
information/ an
gro Mathematical
use an ext
eploy
d
y
y
y
t.
t.
t.
en
en
en
urrentl
urrentl
urrentl
/EEA and UK
elopm
elopm
elopm
EU
but c
but c
but c
of
t, dev
t,
t,
w
er
rvie
Not ye und
Not ye
under dev
Not ye
under dev
Ove
s.
s.
s.
RT
Ye
Ye
Ye
REPO
NICAL
nds
TECH
therla
Malta*
Ne
Norway
ies
ts
e
he
d
tion
19
en
b
:
an
he
istr
e
rse
o t
ng
ev
AK
or
ve
t
f
).
f t
register
o
er
t-19),
ible link n
ry HC) use of
yond
accina
BIV
rted
st
gia
e bei
onsidered.
ce o
e) is
nd
th reg
PH
dicines
egistries
red
oss
ima
llan
of v
dverse
sation will
healthcar s to
epo
egi
atient
p
(be
al
NI
r Pr
gian Ca istry (DÅR
linked t
ilanc
nce a
heal nce of COVID-
n Immunisation
e r n Me
cy r
n p
re (NRP
umentation
rvei
ig t.
tion
d by on
eported ad
alth r
nd a
em being c
stem
en
illa
illa
gia
ted a
si
gia
gia
su
ts ar
y
he
) a
try fo
doc
cination ar
yst is
acov
fes
stry at
ergen
R
th Reg
ed
national
gistry, (SYSVAK).
porte
enc
ata
egis alth Ca
Surve monitoring
- Surve
vaccina Norwe
Re Suspec
after immuni
re pro
regi atient r
even Norwe
Ag
Em
COVID-19 (Be Norwe
(NP with the Norwe
R He
the Norwe Dea
r vac
hen fety sy
harm elopm
fo ined.
tronic s -19 d
sa
p
-
-
-
-
-P
r national -
s on the
em
ec
erm
rengt
Othe
Detail
syst det
An el COVID
A st vaccine
routine under dev
e
s
l
o
ed
to
re
s will b
ery,
ntiona
he
ilar
for s.
ken int .
zation of
t t
al phase
m
ta
si
deliv
onal
aigns a
accine
e initi
, v
eing lanning
organi
mp
n with limit
ined. A
ly
istics,
aig
outine,
ofessi
upp
accinations
are b
d r
v e pr
tion ca term
s s te
s
car
ils on the
ibu
nza th
ge (focus on conve
chain)
str
Deta
vaccina being de
beginning, in th of the camp
vaccine di
influe heal
spects of logA
stora
cold account in the p
-19 vaccine
n
19
D-
oups
he
for COVID
sk gr
24
ation o
n t
r COVI
rts.
n ri
nd
d o
o
s fo
epo
se
ata C r
comme
CD
cal d n E
ation group
iologi d ite
and vaccination plans
NITAG re
unization is ba
en
ent
m
dem es
m
The
prioritis im
epi pr
eploy
e
er
d
risk
al gn
e of
du
ions be
s
orker
ce
pai
an
gh
ath
ndat
ded ov
st
hi
e initi am ccine
si
r de
ups to
een
/EEA and UK
re cours
e c
b
as contact with
e o
gro
EU
lthcare w
ents at eve
comme
d in th f th ed va
te
ave
of
ea
seas
ority
o
mit
d and han
w
H
Social staff in
pati of s
di to COVID-19
es
y h
as
rvie
r pri
ppl
-
-
NITAG re fo
vaccina ph
with li
su finalize
Ove
s.
RT
Ye
REPO
NICAL
TECH
land*
Po
,
s.
r
ions
ct
tion
-19
the
ation
tr
ffe
unde
igilance
gulat
be as e
try
COVID
ll
cov
re
ide
gis
ed for
e
informa
dminis
national ed
s.
ac
a
s will s we le sib
ent.
be us
es
harma
ation
d, a
tion re
n
in pl
onfirm
accine
poss
ge:
tiven
nt p
CO) and
e with the
elopem
em
n c
of
era
ecific COVID-19
ata ca
fec
:
eR o
urveys
bution and
-19 v
Sp vaccina
dev
monitoring of
ef
curre syst
se
cov
:
ba
cordanc stri
-
-D
-
ptance -S
e of Immunis
stry (
ely monitore
gi
ccine
Us
re data
cases.
In ac the di
of COVID clos
monitoring
Va
Safety
Acce
e
ith
el
s
ill
of
o b
nd
s
w
epend
s.
ls
ho
out
up
ture
d
e nt
r
c ectious
as w y.
s w
ristics
ag me
ared by
vited to
and w
a
tions
en in
ined
tion a
gro
inf
of
will a
ing
struc
te
tor
for HCW
publi
e in
gns
edi
rry
accination i
dera
ac ble.
rations
uire
prep
y,
e
itizen
e giv ies
tions fo
s (
b
m chnolog
easonal
tion
accina
e v iority
har aila
req
b
l be
as part
ic
d infra
bl te
s
of ca
d c
th l pr
t.
nd
xpert
ampai
av
c). The def s will
d
ccina
an
es
.
ility
al
/s
conside
ing and s
e facilit
Instruc
f pu tion
ndly v
ag
es will
et
va
ib
nter
tion wil
of e
that to
cinate
p o
ation of
tive)
s i
on the c
s
tical
es,
ered
ccine
ack
dos
t group
el
nza id
oss
ring
pec
es
p
t
roup lth, immunolog
rmation c
erience with th aniz
p
vided
m health an
seas
e h
zen-frie
su
pr
pend
Logis
on conditions a
Firs health car
and LTCF. vaccina
a g hea
di targe
be vac info
th as informa
Exp org
influe cons
The citi
en pro
(fro pers
ex
The logistical consi
de the va
-19 vaccine
.
e
ps:
ent
ccine,
n EU
m
lso b
rou
onsider
l a
accine
f va
nclude s
for COVID
g
e,
xpert
o
e ready
ll a
ch v
25
ill c
ing
ag
ed i
will a
on?)
as wil
al
evelop
y ses) ccine issi
en
er d
s we
a
elling
hese w
y b
gy and
of the
ce on vaccine
f do
sm
te
onsider
ty of ea
. T
ata
icac o o
an
be used
c
fe
tions as be
mod
s two work
oH den
eff N
y d
(
tics of va
o be
.
ha
M
d
ris
will
nda hich h
nd sa
+ e evi
lity
hed.
ation is und
ce t iolog
a
ered
and vaccination plans
nia
is
cy
labl
y an labi
enting tr
racte
elling cination stra
up w
id
ent
abl
ITAG
comme
den
m
Slove
N avai
safet avai
cha (prev
Mod vac
re gro
est
Prioritis
evi epidem
effica
Mathematical cons
eploy
d
s
in
nts
y
ide re
lderly)
t.
alth
orker
taff in re
ca
d e
en
e w
s
res
lly rm
urrentl
/EEA and UK
sk groups
of He
rm ca
ing
s)
-te
s an
elopm
EU
r ri
try
thcar
-te
but c
of
eal
specia
t,
w
H
(includ long
facilitie Othe
(e in long
facilitie
rvie
to Minis July 2020.
-
-
Not ye
under dev
Ove
s.
s.
RT
Ye
Ye
REPO
NICAL
TECH
nia*
ain
Slove
Sp
of
-19. . It
gister tion
COVID ht nowig s IT
egistra
st r ll a
gain
for r
vaccination re
gal as we
dapted
is ongoing
e a
es le
national
accinations a work
ptations.
The will b
all v The
includ ada
ry
n
le,
sis
d
o
nza
ba st
ing
d
rincip
rme
ers
gain
nt
cate nd prima
influe
erfo
di s a
rm the
p
is ongoing
rs. In p
w ce depend
de
fo
be
ntre
ed
nte
well. The
council
Ne
nning
ugh
ce
volv
ro
zation for
Pla
tion ce
are ani
accinations a
-19, as
e in
s
ed.
ly th
e county
org
ht b
ne
ain
r the v
ht now.
M vaccina
healthc the
vaccinations will fo
COVID vaccinations will
by th
organizations. mig
the rig
-19 vaccine
.
on e.
ce
VE,
as
llan
ing
data
used. oing
ence ise
accine
on
for COVID
include
vid
rvei
ill be
26
ble on ed on
ed
l e 19 d
ible v
su
is ong
data
oss
verity of
y.
ced
-19, includ
c. w
e bas
iology
et elling
re availa
onsider
m
ar
COVID-
on p r wa
c han
VID
tional
ity
miologica
O ide
mod
ata a ups
ide evere
o be d en
or C l ep
lization, se
ortal
s unde
m tical
l/ep r s
ce t
s f ica
pita
e,
and vaccination plans
no d
elling work
ng an
ilance. Na
act i
em
ent
ority gro
ks fo
den isti
seas
m
Since pri
clinica ris
Mod imp
Evi ex
syst serolog
surve on hos
di Mathema
eploy
s
d
ar
s
d
d
rs ars an
s of
s of
s of
s of
s of
s of
of
dults
of
0 ye
r
e in
ed)
orker
esident
e an
ye
ver cial
ear
ear ear
ear
ear
ear
ults
priority
s fo
s’ r om worke
ver
ver
ver
ver
ver
ver
rmin
ver 7
thos
ers
are)
e 80
d o d so
years
-risk a
years
he
/EEA and UK
dult e h
e 75 y
e 70 y
e 65 y
k ad
e 60 y
e 55 y
e 50 y
t
ete
e o
roup
e
ing
ar
an an
d o
d o
d o
d o
d o
d o
d
EU
pl ge
lthcare w
ly c
lation (
er a
home
th
work
an
an
an
h-ris er 65
erate
er 65
an
an
an
ing
of
isk g
seas ea
der
ld a c
re
re
st of
pu
eet
w
Peo of a
R severe COVID-19
di H
(includ el
O in
ca Aall thos
of age heal
ca All thos
age
All thos age
All thos age
Hig und
age Mod
und age
All thos age
All thos age
All thos age
Re
po to be
rvie
-
-
-
-
-
-
-
-
-
-
-
-
-
Ove
ogue m
al
di
ITAG
he N
s.
s
RT
Ye
Ye
unication in t
REPO
m
om
c
NICAL
ral
TECH
* O
eden
Sw
UK*